<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34617317</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2230</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>47</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical and experimental dermatology</Title>
          <ISOAbbreviation>Clin Exp Dermatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine.</ArticleTitle>
        <Pagination>
          <StartPage>437</StartPage>
          <EndPage>440</EndPage>
          <MedlinePgn>437-440</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/ced.14970</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sechi</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-3026-2434</Identifier>
            <AffiliationInfo>
              <Affiliation>Dermatology Unit, Ospedale San Bortolo, Vicenza, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>IRCCS University Hospital of Bologna S Orsola-Malpighi Polyclinic Dermatology Division, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum University of Bologna, Bologna, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pierobon</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-6417-2667</Identifier>
            <AffiliationInfo>
              <Affiliation>Section of Dermatology, Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pezzolo</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0003-0121-4812</Identifier>
            <AffiliationInfo>
              <Affiliation>Dermatology Unit, Ospedale San Bortolo, Vicenza, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Germi</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Dermatology Unit, Ospedale San Bortolo, Vicenza, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Trevisan</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Dermatology Unit, Ospedale San Bortolo, Vicenza, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zardo</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Pathology Unit, Ospedale San Bortolo, Vicenza, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Riva</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Pathology Unit, Ospedale San Bortolo, Vicenza, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mondino</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Health and Risk Management, Ospedale San Bortolo, Vicenza, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Naldi</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Dermatology Unit, Ospedale San Bortolo, Vicenza, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Clin Exp Dermatol</MedlineTA>
        <NlmUniqueID>7606847</NlmUniqueID>
        <ISSNLinking>0307-6938</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EPK39PL4R4</RegistryNumber>
          <NameOfSubstance UI="D000090983">2019-nCoV Vaccine mRNA-1273</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N38TVC63NU</RegistryNumber>
          <NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000090983" MajorTopicYN="N">2019-nCoV Vaccine mRNA-1273</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000090982" MajorTopicYN="N">BNT162 Vaccine</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004892" MajorTopicYN="N">Erythema Multiforme</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017514" MajorTopicYN="N">Pityriasis Lichenoides</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010916" MajorTopicYN="N">Pityriasis Rubra Pilaris</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016463" MajorTopicYN="N">Sweet Syndrome</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>7</Day>
          <Hour>7</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34617317</ArticleId>
        <ArticleId IdType="pmc">PMC8652785</ArticleId>
        <ArticleId IdType="doi">10.1111/ced.14970</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Naranjo CA, Busto U, Sellers EM
et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther
1981; 30: 239–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7249508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
McMahon DE, Amerson E, Rosenbach M
et al. Cutaneous reactions reported after Moderna and Pfizer COVID‐19 vaccination: a registry‐based study of 414 cases. J Am Acad Dermatol
2021; 85: 46–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8024548</ArticleId>
            <ArticleId IdType="pubmed">33838206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Darrigade AS, Théophile H, Sanchez‐Pena P
et al. Sweet syndrome induced by SARS‐CoV2 Pfizer‐BioNTech mRNA vaccine. Allergy
2021; 76: 3194–6. 10.1111/all.14981
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/all.14981</ArticleId>
            <ArticleId IdType="pmc">PMC8441847</ArticleId>
            <ArticleId IdType="pubmed">34143448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stone CA Jr, Rukasin CRF, Beachkofsky TM, Phillips EJ. Immune‐mediated adverse reactions to vaccines. Br J Clin Pharmacol
2019; 85: 2694–706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6955412</ArticleId>
            <ArticleId IdType="pubmed">31472022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gunatheesan S, Ferguson J, Moosa Y. Pityriasis lichenoides et varioliformis acuta: a rare association with the measles, mumps and rubella vaccine. Australas J Dermatol
2012; 53: 76–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23157791</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
